Johannes Fruehauf

Dr. Fruehauf is a serial entrepreneur and scientist with a track record in building successful biotechnology companies. He is the owner of Cambridge BioLabs, an early-stage contract research organization in Kendall Square. He is also the Founder & President of LabCentral, a large non-profit shared laboratory for startup life science companies. Before starting ViThera, he was a co-founder of Cequent Pharmaceuticals (sold to Marina Biotech, Nasdaq MRNA) and served as Head of R&D. He serves as a Board Director or advisor to a number of biotechnology companies. He completed his post-doc with Dr. Chiang Li at the Beth Israel Deaconess Medical Center and invented the bacterial RNAi technology transkingdom RNA interference, the only RNAi therapeutic targeting the gastrointestinal tract. Dr. Fruehauf is the author of over 20 peer reviewed publications and is a named inventor on 14 patents related to RNA interference and bacterial therapeutics.